MAPS Europe is delighted to announce that on March 23, 2022, the first site in the United Kingdom was activated and will begin screening patients in our open-label Phase 2 study of MDMA-assisted therapy for PTSD. The team at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London – South London and Maudsley NHS Trust (KCL-SLaM) led by Dr. James Rucker and supported by the UK Chief Investigator Prof. Allan Young, expect to see their first patients in April.
